MARKET

IOVA

IOVA

Iovance Biotherp
NASDAQ
2.200
0.000
0.00%
After Hours: 2.220 +0.02 +0.91% 19:55 12/05 EST
OPEN
2.200
PREV CLOSE
2.200
HIGH
2.250
LOW
2.175
VOLUME
6.62M
TURNOVER
--
52 WEEK HIGH
9.38
52 WEEK LOW
1.639
MARKET CAP
873.33M
P/E (TTM)
-1.8304
1D
5D
1M
3M
1Y
5Y
1D
Analysts Conflicted on These Healthcare Names: MBX Biosciences, Inc. (MBX), Praxis Precision Medicines (PRAX) and Iovance Biotherapeutics (IOVA)
TipRanks · 19h ago
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX)
TipRanks · 19h ago
Weekly Report: what happened at IOVA last week (1124-1128)?
Weekly Report · 4d ago
Iovance (IOVA) Q3 2025 Earnings Call Transcript
NASDAQ · 11/27 22:44
Iovance Biotherapeutics: Several Positives, But Competition Still Threatens
Seeking Alpha · 11/24 17:56
Iovance Biotherapeutics Is Maintained at Overweight by Barclays
Dow Jones · 11/24 14:40
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $9
Benzinga · 11/24 14:30
Iovance Biotherapeutics price target raised to $9 from $4 at Barclays
TipRanks · 11/24 11:30
More
About IOVA
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.

Webull offers Iovance Biotherapeutics Inc stock information, including NASDAQ: IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IOVA stock methods without spending real money on the virtual paper trading platform.